EP1268526A4 - Novel prostate-specific or testis-specific nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods - Google Patents
Novel prostate-specific or testis-specific nucleic acid molecules, polypeptides, and diagnostic and therapeutic methodsInfo
- Publication number
- EP1268526A4 EP1268526A4 EP01922630A EP01922630A EP1268526A4 EP 1268526 A4 EP1268526 A4 EP 1268526A4 EP 01922630 A EP01922630 A EP 01922630A EP 01922630 A EP01922630 A EP 01922630A EP 1268526 A4 EP1268526 A4 EP 1268526A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- specific
- testis
- polypeptides
- diagnostic
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000002405 diagnostic procedure Methods 0.000 title 1
- 102000039446 nucleic acids Human genes 0.000 title 1
- 108020004707 nucleic acids Proteins 0.000 title 1
- 150000007523 nucleic acids Chemical class 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
- 210000002307 prostate Anatomy 0.000 title 1
- 210000001550 testis Anatomy 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US19192900P | 2000-03-24 | 2000-03-24 | |
US191929P | 2000-03-24 | ||
PCT/US2001/009410 WO2001072962A2 (en) | 2000-03-24 | 2001-03-23 | Novel prostate-specific or testis-specific nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1268526A2 EP1268526A2 (en) | 2003-01-02 |
EP1268526A4 true EP1268526A4 (en) | 2004-09-08 |
Family
ID=22707491
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP01922630A Withdrawn EP1268526A4 (en) | 2000-03-24 | 2001-03-23 | Novel prostate-specific or testis-specific nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1268526A4 (en) |
JP (1) | JP2004521602A (en) |
AU (2) | AU4941101A (en) |
CA (1) | CA2403637A1 (en) |
WO (1) | WO2001072962A2 (en) |
Families Citing this family (92)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060052321A1 (en) | 2002-04-05 | 2006-03-09 | Raitano Arthur B | Nucleic acid and corresponding protein entitled 98P4B6 useful in treatment and detection of cancer |
US6329503B1 (en) | 1998-06-01 | 2001-12-11 | Agensys, Inc. | Serpentine transmembrane antigens expressed in human cancers and uses thereof |
US6833438B1 (en) | 1999-06-01 | 2004-12-21 | Agensys, Inc. | Serpentine transmembrane antigens expressed in human cancers and uses thereof |
US20030149531A1 (en) | 2000-12-06 | 2003-08-07 | Hubert Rene S. | Serpentine transmembrane antigens expressed in human cancers and uses thereof |
US20040048798A1 (en) * | 1999-06-01 | 2004-03-11 | Raitano Arthur B. | Nucleic acid and corresponding protein entitle 98P4B6 useful in treatment and detection of cancer |
US20040141975A1 (en) | 1998-06-01 | 2004-07-22 | Raitano Arthur B. | Nucleic acid and corresponding protein entitled 98P4B6 useful in treatment and detection of cancer |
US6835812B1 (en) | 1999-04-29 | 2004-12-28 | University Of Tennessee Research Corporation | Human p-Hyde proteins |
WO2000071564A2 (en) * | 1999-04-29 | 2000-11-30 | The University Of Tennessee Research Corporation | Isolated nucleic acids of the p-hyde family, p-hyde proteins, and methods of inducing susceptibility to induction of cell death in cancer |
US20060073150A1 (en) | 2001-09-06 | 2006-04-06 | Mary Faris | Nucleic acid and corresponding protein entitled STEAP-1 useful in treatment and detection of cancer |
US7611892B2 (en) | 2000-03-24 | 2009-11-03 | President And Fellows Of Harvard College | Prostate-specific or testis-specific nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods |
EP1231216A3 (en) * | 2001-01-30 | 2004-03-17 | Aeomica, Inc. | Human gtp-rho binding protein 2 |
GB2379660A (en) * | 2001-01-30 | 2003-03-19 | Aeomica Inc | Human GTP-Rho binding protein 2 |
US7494646B2 (en) | 2001-09-06 | 2009-02-24 | Agensys, Inc. | Antibodies and molecules derived therefrom that bind to STEAP-1 proteins |
BR0308953A (en) * | 2002-04-05 | 2006-03-14 | Agensys Inc | compositions, protein, polynucleotide, method of generating an immune response, detection method, pharmaceutical composition, antibody or fragment thereof, transgenic animal, hybridoma, method of providing a cytotoxic agent or diagnostic agent and method of inhibiting cell growth cancerous |
JP5840351B2 (en) * | 2002-09-06 | 2016-01-06 | アジェンシス,インコーポレイテッド | Nucleic acids and corresponding proteins referred to as 98P4B6 useful in the treatment and detection of cancer |
EP3120861B1 (en) | 2003-11-06 | 2018-08-15 | Seattle Genetics, Inc. | Intermediate for conjugate preparation comprising auristatin derivatives and a linker |
GB0326834D0 (en) * | 2003-11-18 | 2003-12-24 | Celltech R&D Ltd | A protein involved in lung cancer |
TWI238677B (en) | 2003-12-25 | 2005-08-21 | Fujitsu Ltd | Organic EL element, organic EL display, process for fabricating organic EL element, and device for fabricating organic EL element |
EP1742966B1 (en) | 2004-04-22 | 2013-11-27 | Agensys, Inc. | Antibodies and molecules derived therefrom that bind to steap-1 proteins |
CN102973947A (en) | 2004-06-01 | 2013-03-20 | 健泰科生物技术公司 | Antibody-drug conjugates and methods |
CA2580141C (en) | 2004-09-23 | 2013-12-10 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
US20100111856A1 (en) | 2004-09-23 | 2010-05-06 | Herman Gill | Zirconium-radiolabeled, cysteine engineered antibody conjugates |
AU2005246090A1 (en) * | 2005-02-22 | 2005-12-01 | Biomedisinsk Innovasjon As | STAMP2 nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods |
SI2502938T1 (en) | 2006-10-27 | 2015-05-29 | Genentech, Inc. | Antibodies and immunoconjugates and uses therefor |
US8426673B2 (en) * | 2008-01-11 | 2013-04-23 | Astellas Pharma, Inc. | Pathological animal model for pelvic pain syndrome |
CA2809819A1 (en) | 2009-09-09 | 2011-03-17 | Centrose, Llc | Extracellular targeted drug conjugates |
BR112012026213B1 (en) | 2010-04-15 | 2021-12-28 | Medimmune Limited | PYRROLOBENZODIAZEPINE COMPOUNDS, CONJUGATE THEREOF, PHARMACEUTICAL COMPOSITION INCLUDING CONJUGATE AND USE THEREOF FOR TREATMENT OF A PROLIFERATIVE DISEASE |
AU2011265054B2 (en) | 2010-06-08 | 2016-09-15 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
EP2640727B1 (en) | 2010-11-17 | 2015-05-13 | Genentech, Inc. | Alaninyl maytansinol antibody conjugates |
MX2013013054A (en) | 2011-05-12 | 2014-02-20 | Genentech Inc | Multiple reaction monitoring lc-ms/ms method to detect therapeutic antibodies in animal samples using framework signature peptides. |
CN103987407B (en) | 2011-10-14 | 2016-08-24 | 麦迪穆有限责任公司 | Pyrrolobenzodiazepines Zhuo and conjugate thereof |
WO2013130093A1 (en) | 2012-03-02 | 2013-09-06 | Genentech, Inc. | Biomarkers for treatment with anti-tubulin chemotherapeutic compounds |
AU2013328580B2 (en) | 2012-10-12 | 2016-01-21 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
PL2906298T3 (en) | 2012-10-12 | 2019-04-30 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates |
WO2014057114A1 (en) | 2012-10-12 | 2014-04-17 | Adc Therapeutics Sàrl | Pyrrolobenzodiazepine-anti-psma antibody conjugates |
ES2660029T3 (en) | 2012-10-12 | 2018-03-20 | Medimmune Limited | Antibody-pyrrolobenzodiazepine conjugates |
NZ707490A (en) | 2012-10-12 | 2018-09-28 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-anti-cd22 antibody conjugates |
CA2887894C (en) | 2012-10-12 | 2019-10-29 | Adc Therapeutics Sarl | Pyrrolobenzodiazepine - anti-psma antibody conjugates |
PT2906296T (en) | 2012-10-12 | 2018-06-01 | Medimmune Ltd | Pyrrolobenzodiazepine-antibody conjugates |
ES2658888T5 (en) | 2012-12-21 | 2021-10-19 | Medimmune Ltd | Pyrrolobenzodiazepines and their conjugates |
AU2013366490B9 (en) | 2012-12-21 | 2018-02-01 | Medimmune Limited | Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases |
TWI680766B (en) | 2013-03-13 | 2020-01-01 | 英商梅迪繆思有限公司 | Pyrrolobenzodiazepines and conjugates thereof |
MX364330B (en) | 2013-03-13 | 2019-04-23 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof. |
WO2014140174A1 (en) | 2013-03-13 | 2014-09-18 | Spirogen Sàrl | Pyrrolobenzodiazepines and conjugates thereof |
EP3033111B1 (en) | 2013-08-12 | 2019-03-13 | Genentech, Inc. | 1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment |
GB201317982D0 (en) | 2013-10-11 | 2013-11-27 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
EP3054985B1 (en) | 2013-10-11 | 2018-12-26 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
EP3054986B1 (en) | 2013-10-11 | 2019-03-20 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
EP3054983B1 (en) | 2013-10-11 | 2019-03-20 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
BR112016013258A2 (en) | 2013-12-16 | 2018-01-16 | Genentech Inc | antibody-drug conjugate, pharmaceutical composition, method for treating cancer and kit |
WO2015095223A2 (en) | 2013-12-16 | 2015-06-25 | Genentech, Inc. | Peptidomimetic compounds and antibody-drug conjugates thereof |
PE20161394A1 (en) | 2013-12-16 | 2017-01-06 | Genentech Inc | PEPTIDOMIMETIC COMPOUNDS AND THEIR ANTIBODY-DRUG CONJUGATES |
JP6531166B2 (en) | 2014-09-10 | 2019-06-12 | メドイミューン・リミテッドMedImmune Limited | Pyrrolobenzodiazepine and its conjugate |
WO2016040825A1 (en) | 2014-09-12 | 2016-03-17 | Genentech, Inc. | Anthracycline disulfide intermediates, antibody-drug conjugates and methods |
GB201416112D0 (en) | 2014-09-12 | 2014-10-29 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
SG11201701128YA (en) | 2014-09-12 | 2017-03-30 | Genentech Inc | Cysteine engineered antibodies and conjugates |
SG11201702079UA (en) | 2014-09-17 | 2017-04-27 | Genentech Inc | Pyrrolobenzodiazepines and antibody disulfide conjugates thereof |
MX2017006770A (en) | 2014-11-25 | 2018-02-09 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates. |
JP6752204B2 (en) | 2014-12-03 | 2020-09-09 | ジェネンテック, インコーポレイテッド | Quadruple amine compounds and their antibodies-drug conjugates |
GB201506402D0 (en) | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
GB201506411D0 (en) | 2015-04-15 | 2015-05-27 | Bergenbio As | Humanized anti-axl antibodies |
MA43345A (en) | 2015-10-02 | 2018-08-08 | Hoffmann La Roche | PYRROLOBENZODIAZEPINE ANTIBODY-DRUG CONJUGATES AND METHODS OF USE |
MA43354A (en) | 2015-10-16 | 2018-08-22 | Genentech Inc | CONJUGATE DRUG CONJUGATES WITH CLOUDY DISULPHIDE |
MA45326A (en) | 2015-10-20 | 2018-08-29 | Genentech Inc | CALICHEAMICIN-ANTIBODY-DRUG CONJUGATES AND METHODS OF USE |
GB201601431D0 (en) | 2016-01-26 | 2016-03-09 | Medimmune Ltd | Pyrrolobenzodiazepines |
GB201602359D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
GB201602356D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
US20170315132A1 (en) | 2016-03-25 | 2017-11-02 | Genentech, Inc. | Multiplexed total antibody and antibody-conjugated drug quantification assay |
GB201607478D0 (en) | 2016-04-29 | 2016-06-15 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
EP3458101B1 (en) | 2016-05-20 | 2020-12-30 | H. Hoffnabb-La Roche Ag | Protac antibody conjugates and methods of use |
WO2017205741A1 (en) | 2016-05-27 | 2017-11-30 | Genentech, Inc. | Bioanalytical method for the characterization of site-specific antibody-drug conjugates |
EP3464280B1 (en) | 2016-06-06 | 2021-10-06 | F. Hoffmann-La Roche AG | Silvestrol antibody-drug conjugates and methods of use |
JP7093767B2 (en) | 2016-08-11 | 2022-06-30 | ジェネンテック, インコーポレイテッド | Pyrrolobenzodiazepine prodrug and its antibody conjugate |
EP3522933B1 (en) | 2016-10-05 | 2021-12-15 | F. Hoffmann-La Roche AG | Methods for preparing antibody drug conjugates |
GB201617466D0 (en) | 2016-10-14 | 2016-11-30 | Medimmune Ltd | Pyrrolobenzodiazepine conjugates |
GB201702031D0 (en) | 2017-02-08 | 2017-03-22 | Medlmmune Ltd | Pyrrolobenzodiazepine-antibody conjugates |
DK3544636T3 (en) | 2017-02-08 | 2021-05-10 | Adc Therapeutics Sa | Pyrrolobenzodiazepine antibody conjugates |
RU2019134462A (en) | 2017-04-03 | 2021-05-05 | Ф. Хоффманн-Ля Рош Аг | ANTIBODIES BINDING WITH STEAP-1 |
CN110582505B (en) | 2017-04-18 | 2021-04-02 | 免疫医疗有限公司 | Pyrrolobenzodiazepine conjugates |
CA3057748A1 (en) | 2017-04-20 | 2018-10-25 | Adc Therapeutics Sa | Combination therapy with an anti-axl antibody-drug conjugate |
AU2018285562B2 (en) | 2017-06-14 | 2024-01-18 | Adc Therapeutics Sa | Dosage regimes for the administration of an anti-CD19 ADC |
RS62928B1 (en) | 2017-08-18 | 2022-03-31 | Medimmune Ltd | Pyrrolobenzodiazepine conjugates |
IL273387B2 (en) | 2017-09-20 | 2023-10-01 | Ph Pharma Co Ltd | Thailanstatin analogs |
GB201803342D0 (en) | 2018-03-01 | 2018-04-18 | Medimmune Ltd | Methods |
GB201806022D0 (en) | 2018-04-12 | 2018-05-30 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
GB201814281D0 (en) | 2018-09-03 | 2018-10-17 | Femtogenix Ltd | Cytotoxic agents |
EP3870235A1 (en) | 2018-10-24 | 2021-09-01 | F. Hoffmann-La Roche AG | Conjugated chemical inducers of degradation and methods of use |
JP2022513198A (en) | 2018-12-10 | 2022-02-07 | ジェネンテック, インコーポレイテッド | Photocrosslinkable peptide for site-specific conjugation to Fc-containing proteins |
GB201901197D0 (en) | 2019-01-29 | 2019-03-20 | Femtogenix Ltd | G-A Crosslinking cytotoxic agents |
GB2597532A (en) | 2020-07-28 | 2022-02-02 | Femtogenix Ltd | Cytotoxic compounds |
AR128331A1 (en) | 2022-01-26 | 2024-04-17 | Genentech Inc | CHEMICAL DEGRADATION INDUCTORS CONJUGATED WITH ANTIBODIES AND METHODS OF THESE |
AR128330A1 (en) | 2022-01-26 | 2024-04-17 | Genentech Inc | CHEMICAL DEGRADATION INDUCERS CONJUGATED WITH ANTIBODY AND METHODS OF THESE |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999062941A2 (en) * | 1998-06-01 | 1999-12-09 | Urogenesys, Inc. | Serpentine transmembrane antigens expressed in human cancers and uses thereof |
WO2000073509A2 (en) * | 1999-06-01 | 2000-12-07 | Incyte Genomics, Inc. | Molecules for diagnostics and therapeutics |
WO2001005970A2 (en) * | 1999-07-19 | 2001-01-25 | Incyte Genomics, Inc. | Gtp-binding protein associated factors |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5599686A (en) * | 1994-06-28 | 1997-02-04 | Merck & Co., Inc. | Peptides |
US5820880A (en) * | 1995-06-07 | 1998-10-13 | The United States Of America As Represented By The Secretary Of The Army | Liposomal formulation |
US6048970A (en) * | 1998-05-22 | 2000-04-11 | Incyte Pharmaceuticals, Inc. | Prostate growth-associated membrane proteins |
-
2001
- 2001-03-23 EP EP01922630A patent/EP1268526A4/en not_active Withdrawn
- 2001-03-23 CA CA002403637A patent/CA2403637A1/en not_active Abandoned
- 2001-03-23 AU AU4941101A patent/AU4941101A/en active Pending
- 2001-03-23 JP JP2001571877A patent/JP2004521602A/en not_active Withdrawn
- 2001-03-23 AU AU2001249411A patent/AU2001249411B2/en not_active Ceased
- 2001-03-23 WO PCT/US2001/009410 patent/WO2001072962A2/en active IP Right Grant
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999062941A2 (en) * | 1998-06-01 | 1999-12-09 | Urogenesys, Inc. | Serpentine transmembrane antigens expressed in human cancers and uses thereof |
WO2000073509A2 (en) * | 1999-06-01 | 2000-12-07 | Incyte Genomics, Inc. | Molecules for diagnostics and therapeutics |
WO2001005970A2 (en) * | 1999-07-19 | 2001-01-25 | Incyte Genomics, Inc. | Gtp-binding protein associated factors |
Non-Patent Citations (6)
Title |
---|
DATABASE EMBL [online] EBI; 10 December 1999 (1999-12-10), EMMANUEL DIAS NETO ET AL: "SHOTGUN SEQUENCING OF THE HUMAN TRANSCRIPTOME WITH ORF EXPRESSED SEQUENCE TAGS", XP002279053, Database accession no. AI908168 * |
DATABASE EMBL [online] EBI; 22 February 2000 (2000-02-22), ISOGAI T., OTSUKI T., XP002241852, Database accession no. AK001691 * |
DATABASE EMBL [online] EBI; 26 April 1999 (1999-04-26), MAHAIRAS G.G ET AL.: "Sequence-tagged connectors...", Database accession no. AQ456610 * |
DIATCHENKO L ET AL: "SUPPRESSION SUBTRACTIVE HYBRIDIZATION: A METHOD FOR GENERATING DIFFERENTIALLY REGULATED OR TISSUE-SPECIFIC CDNA PROBES AND LIBRARIES", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 93, 1 June 1996 (1996-06-01), pages 6025 - 6030, XP002911922, ISSN: 0027-8424 * |
MAHAIRAS G G ET AL: "SEQUENCE-TAGGED CONNECTORS: A SEQUENCE APPROACH TO MAPPING AND SCANNING THE HUMAN GENOME", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 96, no. 17, AQ456610, August 1999 (1999-08-01), pages 9739 - 9744, XP002175436, ISSN: 0027-8424 * |
WATANABE G ET AL: "PROTEIN KINASE N (PKN) AND PKN-RELATED PROTEIN RHOPHILIN AS TARGETS OF SMALL GTPASE RHO", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US, vol. 271, no. 5249, 2 February 1996 (1996-02-02), pages 645 - 648, XP001109460, ISSN: 0036-8075 * |
Also Published As
Publication number | Publication date |
---|---|
EP1268526A2 (en) | 2003-01-02 |
AU2001249411B2 (en) | 2007-02-15 |
JP2004521602A (en) | 2004-07-22 |
WO2001072962A2 (en) | 2001-10-04 |
CA2403637A1 (en) | 2001-10-04 |
WO2001072962A3 (en) | 2002-01-17 |
AU2001249411B9 (en) | 2001-10-08 |
AU4941101A (en) | 2001-10-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU4941101A (en) | Novel prostate-specific or testis-specific nucleic acid molecules, polypeptides,and diagnostic and therapeutic methods | |
AU3510200A (en) | Human dickkopf-related protein and nucleic acid molecules and uses therefor | |
EP1186615A4 (en) | Novel protein and dna thereof | |
EP1425289A4 (en) | Novel nucleic acid and polypeptide molecules | |
AU2001250999A1 (en) | Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof | |
EP1058737A4 (en) | Novel fdrg protein and nucleic acid molecules and uses therefor | |
AU2002213450A1 (en) | Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof | |
AU2002239256A1 (en) | Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof | |
EP1293568A4 (en) | Novel protein and dna thereof | |
GB2349150B (en) | Expression of DNA or proteins in C. Elegans | |
NO20020919L (en) | Iren protein, its preparation and use | |
EP1383871A4 (en) | Isolated human enzyme proteins, nucleic acid molecules encoding human enzyme proteins, and uses thereof | |
AU2001290872A1 (en) | Isolated human kinase proteins, nucleic acid molecules and uses thereof | |
EP1383875A4 (en) | Isolated human nadph oxidase, nucleic acid molecules encoding said proteins, and uses thereof | |
AU2003298570A8 (en) | Isolated human hepsin/46 proteins, nucleic acid molecules encoding human hepsin/46 proteins, and uses thereof | |
AU2001271276A1 (en) | Isolated human aminotransferase proteins, nucleic acid molecules encoding human aminotransferase proteins, and uses thereof | |
EP1329504A4 (en) | Nucleic acid of novel human kinesin-associated gene, protein encoded by the nucleic acid, peptide fragment thereof and anticancer agents comprising the nucleic acid and the like | |
EP1385991A4 (en) | Isolated human enzyme proteins, nucleic acid molecules encoding human enzyme proteins, and uses thereof | |
EP1383908A4 (en) | Isolated human enzyme proteins, nucleic acid molecules encoding human enzyme proteins, and uses thereof | |
EP1383877A4 (en) | Isolated human enzyme proteins, nucleic acid molecules encoding human enzyme proteins, and uses thereof | |
EP1383876A4 (en) | Isolated human enzyme proteins, nucleic acid molecules encoding human enzyme proteins, and uses thereof | |
EP1228085A4 (en) | Gridlock nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods | |
EP1390486A4 (en) | Isolated human aminoacylase, nucleic acid molecules encoding human aminoacylase, and uses thereof | |
EP1447411A4 (en) | Novel protein, its dna and use thereof | |
AU2002234023A1 (en) | Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20021023 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
AX | Request for extension of the european patent |
Free format text: AL;LT;LV;MK;RO;SI |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: 7A 61K 38/00 B Ipc: 7C 07K 14/72 B Ipc: 7G 01N 33/53 A |
|
RBV | Designated contracting states (corrected) |
Designated state(s): AT BE CH DE FR GB LI |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20040727 |
|
17Q | First examination report despatched |
Effective date: 20070503 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20071114 |